The Effects of Huang-Lian-Jie-Du-Tang（HLJDT) on the Survival of Patients With Multiple Myeloma in Maintain Therapy (HLJDT-2016)

Wuhan University

Status and phase: Unknown; Phase 1

Conditions: Multiple Myeloma

Treatments: Drug: Thalidomide; Drug: HLJDT

Study type: Interventional

Funder types: Other

Identifiers

NCT02467647

HLJDT-2016

Details and patient eligibility

About

To investigate the efficacy of the combination of Thalidomide and Huang-Lian-Jie-Du-Tang on the patients with multiple myeloma in maintain therapy.

Enrollment: 500 estimated patients

Sex: All

Ages: 20 to 85 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• patients can take HLJDT

Exclusion criteria

• patients can not take HLJDT

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Crossover Assignment

Masking: Single Blind

---

500 participants in 2 patient groups

A

Experimental group

Description:

Arm A: HLJDT 150ml three times per day for 6 months and Thalidomide 100mg once per day for 6 months

Treatment:

Drug: Thalidomide

Drug: HLJDT

B

Active Comparator group

Description:

Arm B: Thalidomide 100mg oral once per day for 6 months

Treatment:

Drug: Thalidomide